CliffBio
small molecule

ZENBEXUS

IBERDOMIDE HYDROCHLORIDE

Loss of exclusivityAugust 2031FDA regulatory exclusivity expiry
CompanyBRISTOL MYERS SQUIBB CO

Drug detail

Brand nameZENBEXUS
Active ingredientIBERDOMIDE HYDROCHLORIDE
StrengthEQ 0.75MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2026
Marketing statusRX

Regulatory exclusivity

CodeExpires
NCEAugust 2031

More from BRISTOL MYERS SQUIBB CO

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.